ArticlePharmacoEconomics - open2023

Healthcare Payer Perspectives on the Assessment and Pricing of Oncology Multi-Indication Products: Evidence from Nine OECD Countries.

Mackenzie Mills et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.